Log In

Forgot Password?

OR

Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

Abstract Details

Lasmiditan is Effective in the Acute Treatment of Migraine in Patients with Insufficient Response to Triptans: Findings from the CENTURION Study
Headache
Headache Posters (7:00 AM-5:00 PM)
037
Lasmiditan is a selective 5-HT1F receptor agonist, approved by the FDA for the acute treatment of migraine. It may be an option for TIRs, a group with potentially unmet medical need.

To assess the efficacy of lasmiditan in triptan insufficient responders (TIRs).

CENTURION was a modified-parallel, placebo-controlled, double-blind, Phase 3 consistency study of patients with migraine, with or without aura, randomized to lasmiditan (LTN) 200mg for 4 attacks, LTN100 for 4 attacks, or placebo for 3 and LTN50 for 1 attack. TIRs were a pre-defined subset with an inconsistent response to their most recent triptan, were taking a triptan and had a poor/very poor migraine Treatment Optimization Questionnaire (mTOQ-6) score, or had discontinued their most recent triptan because of efficacy/tolerability issues or contraindications. Pain freedom at 2 hours (h) in the TIR population was a gated secondary endpoint.  Results are provided for the first attack through 2h post dose and for sustained effects, through 48h, and for consistency of response defined as achieving the outcome at 2h in ≥2/3 attacks.

During the first attack, both lasmiditan doses showed statistically-significantly benefit over placebo for pain freedom beginning at 1h, and for pain relief beginning at 0.5h (LTN200) or 1h (LTN100)(p<0.05). For pain freedom at 2h (gated): placebo, 8.8%; LTN100, 24.0% (OR 3.3 [1.8-6.0]; LTN200, 25.6% (OR 3.6 [2.0-6.4])(p<0.001). Both lasmiditan doses showed statistically-significant benefit for consistency of effect across attacks for pain freedom and pain relief at 2h. Statistically-significant differences from placebo were evident for one or both lasmiditan doses for migraine-related disability freedom at 2h, much/very much better on the Patient Global Impression of Change at 2h, most bothersome symptom freedom at 2h, need for rescue medication, and sustained pain freedom at 24 and 48h (p<0.05).
Lasmiditan was efficacious across multiple clinically relevant endpoints in TIRs.
Authors/Disclosures
Uwe Reuter
PRESENTER
Uwe Reuter has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Allergan. Uwe Reuter has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Abbvie. Uwe Reuter has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis. Uwe Reuter has received personal compensation in the range of $500-$4,999 for serving as a Consultant for TEVA. Uwe Reuter has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Liily Deutschland. Uwe Reuter has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amgen. Uwe Reuter has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Allergan/Abbvie. Uwe Reuter has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lilly. Uwe Reuter has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TEVA. Uwe Reuter has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. The institution of Uwe Reuter has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lundbeck. Uwe Reuter has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Allergan. Uwe Reuter has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Lilly. Uwe Reuter has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Medscape . Uwe Reuter has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Novartis. Uwe Reuter has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for StreaMEdUp. Uwe Reuter has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Teva. The institution of Uwe Reuter has received research support from Novartis.
Louise Lombard Louise Lombard has received personal compensation for serving as an employee of Eli Lilly.
John H. Krege John H. Krege has received personal compensation for serving as an employee of Eli Lilly. John H. Krege has received stock or an ownership interest from Eli Lilly.
Judith Krikke (Eli Lilly and Company) Judith Krikke has received personal compensation for serving as an employee of Eli Lilly and Company.
Stefan Wilhelm (Lilly Deutschland GmbH) Stefan Wilhelm has received personal compensation for serving as an employee of Eli Lilly. Stefan Wilhelm has received stock or an ownership interest from Eli Lilly.
Amy J Kovacik Amy J Kovacik has nothing to disclose.
Qun Lin Qun Lin has received personal compensation for serving as an employee of Eli Lilly and Company. Qun Lin has received stock or an ownership interest from Eli Lilly and company .
Sherie A. Dowsett Sherie A. Dowsett has received personal compensation for serving as an employee of Eli Lilly and Company. Sherie A. Dowsett has received stock or an ownership interest from Eli Lilly and Company.
Dawn C. Buse, PhD (Dawn C. Buse, PhD) Dr. Buse has received personal compensation for serving as an employee of Vector Psychometric Group. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbvie-Allergan. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amgen. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lilly. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lundbeck. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Collegium. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Teva. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lilly. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abbvie-Allergan. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lundbeck. Dr. Buse has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Current Pain and Headache Reports. The institution of Dr. Buse has received research support from Amgen. The institution of Dr. Buse has received research support from FDA. The institution of Dr. Buse has received research support from National Headache Foundation.